The University Of Texas System

Baxter International Inc.

Inex Pharmaceuticals Corporation

Quadra Logic Technologies, Inc.

Hana Biosciences, Inc.

Other

Qlt Inc.

Talon Therapeutics, Inc.

Kretzler, Matthias

Patricia M Logan

Murray S Webb

Andreas H Sarris

Fernando Cabanillas

James H Goldie

Clive T R Burge

John R Chapman

Janice North

Herma C Neyndorff

Lawrence D Mayer

Thomas D Madden

Sean C Semple

Sandra K Klimuk

Jeffery Jerome Wheeler

Quet F Ahkong

Gabriel Bela Kalmar

Ljiljana Kojic

Kymberley L Sutton

G Michael Vincent

Matthias Kretzler

Clive T Burge

This invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of lymphomas, including relapsed forms of non-Hodgkin's Lymphoma. These methods involve the administration of liposome-encapsulated vinca alkaloids, e.g., vincristine, to a mammal with a lymphoma.

Compositions and methods for treating lymphoma

Methods are provided to specifically modulate the activation of monocytes and/or macrophages. Administration of integrin linked kinase (ILK) blocking agents; compounds that otherwise prevent the binding of natural ILK ligands to ILK; or compounds that prevent expression of, or signaling through ILK exert an anti-inflammatory effect by inhibiting iNOS and COX-2 expression, at the level of transcription by suppressing the activation of NF-&#x3ba;B. The modulation of activation through ILK is used to regulate immune processes at targeted sites, for example to decrease undesirable inflammatory responses.

Integrin linked kinase modulation of monocyte activation

This invention provides compositions and methods for treating neoplasias in a mammal. In particular, the invention provides liposome-encapsulated vinca alkaloids, e.g., vinorelbine, and methods of treating a mammal using such compositions.

Compositions and methods for treating cancer

The present invention provides a method for inactivating pathogens in a body fluid, such as plasma, red cells, platelets, leukocytes, and bone marrow. The present invention minimizes adverse effects caused by the photosensitive agents while retaining the disinfecting activity of such agents and processes. Pursuant to the present invention, prior to irradiating a body fluid including a photoactive drug, the extracellular fluid, which in the case of blood components includes plasma proteins is at least substantially reduced. Additionally, after the irradiation process, the resultant body fluid is prevented from contacting additional extracellular fluid, e.g., plasma proteins, for a predefined period.

Method for inactivating pathogens in compositions containing cells and

A method to inhibit the development of intimal hyperplasia following vascular intervention procedures (angioplasty) is disclosed. The method consists essentially of administering a green porphyrin to the subject concurrent with and following the angioplasty. No purposeful irradiation with light absorbed by the green porphyrin is required or employed in the method.

Method to inhibit restenosis

Method for inactivating pathogens in erythrocytes using photoactive

Growing community of inventors

Vancouver, Canada

Patricia M Logan